A nurse is reviewing the medication history of a client who has a new prescription for colchicine. Which of the following medications increases the client's risk when used in combination with colchicine for developing rhabdomyolysis?

A. The heart rate has increased from 92/min on Day 1 to 108/min on Day 2. This significant increase warrants immediate follow-up as it may indicate pain, anxiety, or an underlying physiological issue such as hemorrhage, infection, or cardiac complications.

D. The temperature has increased from 36.4°C (97.5°F) on Day 1 to 37.2°C (98.9°F) on Day 2. While this increase is within a relatively normal range, it is approaching a fever range (> 38°C or 100.4°F) and warrants further evaluation to determine if there is an underlying infection or inflammation.

B. The oxygen saturation remains relatively stable, from 95% on Day 1 to 96% on Day 2. While it is important to monitor oxygen saturation, the minimal change does not indicate an immediate concern. However, it should still be monitored closely for any further decrease.

C. Edema is not directly mentioned in the provided data. While edema can be indicative of various health issues, there is no evidence in the given information to suggest its presence or severity as a concern requiring immediate follow-up.

E. Urine color is not provided in the given data. While changes in urine color can indicate dehydration or other health issues, it is not mentioned in the assessment findings and therefore not a factor for immediate follow-up based on the information provided.

F Pedal pulses were noted as +2 on Day 1, indicating that they were present and normal. Unless there is a significant change in pedal pulses or signs of vascular compromise, such as decreased or absent pulses, there is no immediate need for follow-up based on the given information.

D. Atorvastatin is a statin medication used to lower cholesterol levels and reduce the risk of cardiovascular events. Statins, including atorvastatin, have been associated with an increased risk of rhabdomyolysis, particularly when used in high doses or in combination with other medications that can interact to increase statin levels in the blood.

A. There is no direct evidence to suggest that omeprazole increases the risk of rhabdomyolysis when used in combination with colchicine.

B. There is limited evidence to suggest that hydrochlorothiazide significantly increases the risk of rhabdomyolysis when used in combination with colchicine.

C. There is no direct evidence to suggest that carvedilol increases the risk of rhabdomyolysis when used in combination with colchicine.